We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panel Votes No on Genetic Test for Opioid Misuse Risk
FDA Panel Votes No on Genetic Test for Opioid Misuse Risk
An FDA advisory panel has voted 11-2 against approval of SOLVD Health’s De Novo request to market AvertD, a genotype test to identify patients at increased risk of opioid use disorder (OUD).